Combination of CD40 Agonism and CSF-1R Blockade Reconditions Tumor-Associated Macrophages and Drives Potent Antitumor Immunity

被引:136
|
作者
Wiehagen, Karla R. [1 ]
Girgis, Natasha M. [1 ,2 ]
Yamada, Douglas H. [1 ]
Smith, Andressa A. [1 ]
Chan, Szeman Ruby [1 ]
Grewal, Iqbal S. [1 ]
Quigley, Michael [1 ,3 ]
Verona, Raluca I. [1 ]
机构
[1] Janssen Res & Dev, Spring House, PA USA
[2] Constellat Pharmaceut, Cambridge, MA USA
[3] Bristol Myers Squibb, Princeton, NJ USA
关键词
T-CELL RESPONSES; INFILTRATING MACROPHAGES; PANCREATIC-CANCER; DENDRITIC CELLS; IN-VIVO; ANTIBODY; LIGAND; IMMUNOTHERAPY; ACTIVATION; THERAPY;
D O I
10.1158/2326-6066.CIR-17-0258
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Efficacious antitumor immune responses must overcome multiple suppressive mechanisms in the tumor micro-environment to control cancer progression. In this study, we demonstrate that dual targeting of suppressive myeloid populations by inhibiting CSF-1/CSF-1R signaling and activation of antigen-presenting cells with agonist anti-CD40 treatment confers superior antitumor efficacy and increased survival compared with monotherapy treatment in preclinical tumor models. Concurrent CSF-1R blockade and CD40 agonism lead to profound changes in the composition of immune infiltrates, causing an overall decrease in immunosuppressive cells and a shift toward a more inflammatory milieu. Anti-CD40/anti-CSF-1R-treated tumors contain decreased tumor-associated macrophages and Foxp3(+) regulatory T cells. This combination approach increases maturation and differentiation of proinflammatory macrophages and dendritic cells and also drives potent priming of effector T cells in draining lymph nodes. As a result, tumor-infiltrating effector T cells exhibit improved responses to tumor antigen rechallenge. These studies show that combining therapeutic approaches may simultaneously remove inhibitory immune populations and sustain endogenous antitumor immune responses to successfully impair cancer progression. (C) 2017 AACR.
引用
收藏
页码:1109 / 1121
页数:13
相关论文
共 50 条
  • [1] Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy
    Dammeijer, Floris
    Lievense, Lysanne A.
    Kaijen-Lambers, Margaretha E.
    van Nimwegen, Menno
    Bezemer, Koen
    Hegmans, Joost P.
    van Hall, Thorbald
    Hendriks, Rudi W.
    Aerts, Joachim G.
    CANCER IMMUNOLOGY RESEARCH, 2017, 5 (07) : 535 - 546
  • [2] The combination of CD40 agonism and PD-L1 blockade enhances antitumor immunity in a mouse syngeneic orthotopic pancreatic tumor model
    Luheshi, Nadia
    Coates-Ulrichsen, Jane
    Harper, James
    Davies, Gareth
    Legg, James
    Wilkinson, Robert
    CANCER RESEARCH, 2015, 75
  • [3] CSF-1R Expression in Tumor-Associated Macrophages Is Associated With Worse Prognosis in Classical Hodgkin Lymphoma
    Koh, Young Wha
    Park, Chansik
    Yoon, Dok Hyun
    Suh, Cheotwon
    Huh, Jooryung
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2014, 141 (04) : 573 - 583
  • [4] Sustained inhibition of CSF1R signaling augments antitumor immunity through inhibiting tumor-associated macrophages
    Sato, Takahiko
    Sugiyama, Daisuke
    Koseki, Jun
    Kojima, Yasuhiro
    Hattori, Satomi
    Sone, Kazuki
    Nishinakamura, Hitomi
    Ishikawa, Tomohiro
    Ishikawa, Yuichi
    Kato, Takuma
    Kiyoi, Hitoshi
    Nishikawa, Hiroyoshi
    JCI INSIGHT, 2025, 10 (01)
  • [5] High Expression of CSF-1R Predicts Poor Prognosis and CSF-1Rhigh Tumor-Associated Macrophages Inhibit Anti-Tumor Immunity in Colon Adenocarcinoma
    Wang, Xingchao
    Zhang, Jianfeng
    Hu, Baoying
    Qian, Fei
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [6] Targeted systemic dendrimer delivery of CSF-1R inhibitor to tumor-associated macrophages improves outcomes in orthotopic glioblastoma
    Liaw, Kevin
    Reddy, Rajsekhar
    Sharma, Anjali
    Li, Jiangyu
    Chang, Michelle
    Sharma, Rishi
    Salazar, Sebastian
    Kannan, Sujatha
    Kannan, Rangaramanujam M.
    BIOENGINEERING & TRANSLATIONAL MEDICINE, 2021, 6 (02)
  • [7] Metabolic reprogramming of hypoxic tumor-associated macrophages through CSF-1R targeting favors treatment efficiency in colorectal cancers
    Gharzeddine, Khaldoun
    Prieto, Cristina Gonzalez
    Malier, Marie
    Hennot, Clara
    Grespan, Renata
    Yamaryo-Botte, Yoshiki
    Botte, Cyrille Y.
    Thomas, Fabienne
    Laverriere, Marie-Helene
    Girard, Edouard
    Roth, Gael
    Millet, Arnaud
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (09)
  • [8] Genetic and Pharmacological Targeting of CSF-1/CSF-1R Inhibits Tumor-Associated Macrophages and Impairs BRAF-Induced Thyroid Cancer Progression
    Ryder, Mabel
    Gild, Matti
    Hohl, Tobias M.
    Pamer, Eric
    Knauf, Jeff
    Ghossein, Ronald
    Joyce, Johanna A.
    Fagin, James A.
    PLOS ONE, 2013, 8 (01):
  • [9] ICOS costimulation in combination with CTLA-4 blockade remodels tumor-associated macrophages toward an antitumor phenotype
    Sharma, Naveen
    Fan, Xiaozhou
    Atolagbe, Oluwatomisin T.
    Ge, Zhongqi
    Dao, Kelly N.
    Sharma, Padmanee
    Allison, James P.
    JOURNAL OF EXPERIMENTAL MEDICINE, 2024, 221 (04):
  • [10] Remodeling tumor immune microenvironment via targeted blockade of PI3K-γ and CSF-1/CSF-1R pathways in tumor associated macrophages for pancreatic cancer therapy
    Li, Man
    Li, Mengmeng
    Yang, Yiliang
    Liu, Yingke
    Xie, Hanbing
    Yu, Qianwen
    Tian, Lifeng
    Tang, Xian
    Ren, Kebai
    Li, Jianping
    Zhang, Zhirong
    He, Qin
    JOURNAL OF CONTROLLED RELEASE, 2020, 321 : 23 - 35